3434-33-1

Basic information

• Product Name: PROSTAGLANDIN E1 METHYL ESTER
• Synonyms: PROSTAGLANDIN E1 METHYL ESTER;(13E,15S)-11α,15-Dihydroxy-9-oxoprost-13-en-1-oic acid methyl ester;7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxy-1-octenyl]-5-oxocyclopentyl]heptanoic acid methyl ester
• CAS NO: 3434-33-1
• Molecular Formula: C₂₁H₃₆O₅
• Molecular Weight: 368.51
• Mol File: 3434-33-1.mol
• Article Data: 25

Chemical Properties

• Appearance: /
• Storage Temp.: −20°C
• CAS DataBase Reference: PROSTAGLANDIN E1 METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: PROSTAGLANDIN E1 METHYL ESTER(3434-33-1)
• EPA Substance Registry System: PROSTAGLANDIN E1 METHYL ESTER(3434-33-1)

Safety Data

• Hazard Codes: F,Xn
• Statements: 11-20/21/22-36/37/38
• Safety Statements: 16-26-36/37/39
• Hazardous Substances Data: 3434-33-1(Hazardous Substances Data)

Upstream product

• 116-11-0 2-Methoxypropene 
• 40098-26-8 methyl 7-(3-hydroxy-5-oxocyclopent-1-en-1-yl)heptanoate 
• 39647-87-5 (E)-(S)-1-Iodo-3-(1-methoxy-1-methyl-ethoxy)-oct-1-ene 
• 77493-14-2 11,15-bis-O-(tetrahydropyran-2-yl)PGE₁ methyl ester 
• 1404361-73-4 (E)-methyl 9-nitronon-8-enoate 
• 1450932-99-6 C₂₁H₃₄O₅ 
• 1450933-01-3 C₂₁H₃₅NO₅ 
• 1450932-97-4 methyl 7-((1S,5R)-5-((3S,1E)-3-hydroxyoct-1-enyl)-2-nitrocyclopent-2-enyl)heptanoate 
• 16887-11-9 prostaglandin A₁ methyl ester 
• 891488-56-5 methyl 8-hydroxy-9-nitro nonanoate 
• 154633-82-6 7-{(1S,2R,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-(S)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-5-oxo-cyclopentyl}-heptanoic acid methyl ester 
• 86982-75-4 7-{(1R,2R,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-(S)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-5-oxo-cyclopentyl}-heptanoic acid methyl ester 
• 41138-61-8 (4R)-4-hydroxy-2-(6-methoxycarbonylhexyl)cyclopent-2-enone 
• 39178-64-8 (E)-1-iodo-1-octen-3-one 

Downstream Products

• 745-65-3 ALPROSTADIL 

Relevant articles and documents

Total synthesis of prostaglandins. IV. A completely stereospecific synthesis of prostaglandin E.

-

A SHORT SYNTHESIS OF (-)-PROSTAGLANDIN E1

(-)-Prostaglandin E1 has been prepared from (R)-4-t-butyldimethylsiloxy-2-cyclopentenone by using as a key operation the tandem organocopper conjugate addition/nitroolefin Michael trapping of the resulting enolate intermediate.

A prostaglandin E1 methyl ester freeze dried preparation for injection and its preparation and use (by machine translation)

The present invention provides a prostaglandin E1 methyl ester freeze dried preparation for injection and preparation and application. The freeze-dried preparation comprises the following parts by weight ingredient: prostaglandin E1 methyl ester 0.1 - 10 parts, oil for injection 500 - 4000 parts, emulsifier 500 - 2000 parts, emulsifier 0 - 10 parts, lyophilized vaccine 5000 - 50000 parts, and glycerin 200 - 1500 parts. The invention prostaglandin E1 methyl ester freeze-dried agent has stimulate the blood vessel small, good stability of the medicine, and compared with similar prostaglandin E1 product just excellent pharmaceutical activity and the therapeutic effect. (by machine translation)

Nitrostated and nitrosylated prostaglandins, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.